$2.32 1.1%
CRBU Stock Price vs. AI Score
Data gathered: July 23

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.


Caribou Biosciences
Price $2.32
Target Price Sign up
Volume 2,340,000
Market Cap $207M
Year Range $1.56 - $8.26
Dividend Yield 0%
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '242.4M15M-12M-41M-46M-0.460
Q4 '2319M9.7M9.1M-35M-35M-0.390
Q3 '2324M9.7M14M-10M-15M-0.120
Q2 '233.8M10M-6.4M-30M-33M-0.480
Q1 '233.5M8.9M-5.4M-28M-31M-0.460

Insider Transactions View All

Rizvi Syed Ali-aamir filed to sell 59,373 shares at $6.3.
January 20 '23
Fischesser Ryan filed to sell 110,366 shares at $10.8.
October 7 '22
Kanner Steven filed to sell 302,059 shares at $11.2.
August 26 '22
Fischesser Ryan filed to buy 102,264 shares at $2.7.
January 12 '22
Fischesser Ryan filed to buy 109,082 shares at $4.1.
January 12 '22

What is the Market Cap of Caribou Biosciences?

The Market Cap of Caribou Biosciences is $207M.

What is the current stock price of Caribou Biosciences?

Currently, the price of one share of Caribou Biosciences stock is $2.32.

How can I analyze the CRBU stock price chart for investment decisions?

The CRBU stock price chart above provides a comprehensive visual representation of Caribou Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Caribou Biosciences shares. Our platform offers an up-to-date CRBU stock price chart, along with technical data analysis and alternative data insights.

Does CRBU offer dividends to its shareholders?

As of our latest update, Caribou Biosciences (CRBU) does not offer dividends to its shareholders. Investors interested in Caribou Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Caribou Biosciences?

Some of the similar stocks of Caribou Biosciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.